Pasireotide

CAS No. 396091-73-9

Pasireotide( SOM 230 | SOM 320 )

Catalog No. M14362 CAS No. 396091-73-9

A potent, stable cyclohexapeptide somatostatin mimic that exhibits unique high-affinity binding to human somatostatin receptors.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
100MG Get Quote In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    Pasireotide
  • Note
    Research use only, not for human use.
  • Brief Description
    A potent, stable cyclohexapeptide somatostatin mimic that exhibits unique high-affinity binding to human somatostatin receptors.
  • Description
    A potent, stable cyclohexapeptide somatostatin mimic that exhibits unique high-affinity binding to human somatostatin receptors (pKi=8.2/9.0/9.1/<7.0/9.9 for sst1/2/3/4/5, respectively); effectively inhibits GHRH-induced growth hormone release in primary cultures of rat pituitary cells with IC50 of 0.4 nM, also potently suppresses GH secretion in rats.Cushing's Disease Approved.
  • In Vitro
    Pasireotide exhibits unique high-affinity binding to human somatostatin receptors (subtypes sst1/2/3/4/5, pKi=8.2/9.0/9.1/<7.0/9.9, respectively).Pasireotide effectively inhibits the growth hormone releasing hormone (GHRH) induced growth hormone (GH) release in primary cultures of rat pituitary cells, with an IC50 of 0.4 nM.
  • In Vivo
    Pasireotide (160 mg/kg/mouth; s.c. for 4 months) significantly decreases the serum insulin, increases serum glucose, reduces the tumor size and increases apoptosis in Pdx1-Cre.Pasireotide (2-50 μg/kg; s.c. twice daily for 42 days) exerts the antinociceptive and antiinflammatory actions via the SSTR2 receptor in a mouse model of immune-mediated arthritis. Animal Model:12 month-old conditional Men1 knockout mice with insulinoma Dosage:160 mg/kg/mouth Administration:S.c. every month for 4 monthsResult:Decreased the serum insulin from 1.060 μg/L to 0.3653 μg/L and increased the serum glucose from 4.246 mM to 7.122 mM.Significantly reduced the tumor size and increased apoptosis.
  • Synonyms
    SOM 230 | SOM 320
  • Pathway
    GPCR/G Protein
  • Target
    Somatostatin Receptor
  • Recptor
    Somatostatin Receptor
  • Research Area
    Endocrinology
  • Indication
    Cushing Disease

Chemical Information

  • CAS Number
    396091-73-9
  • Formula Weight
    1047.206
  • Molecular Formula
    C58H66N10O9
  • Purity
    >98% (HPLC)
  • Solubility
    10 mM in DMSO
  • SMILES
    C1C(CN2C1C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C2=O)CC3=CC=CC=C3)CC4=CC=C(C=C4)OCC5=CC=CC=C5)CCCCN)CC6=CNC7=CC=CC=C76)C8=CC=CC=C8)OC(=O)NCCN
  • Chemical Name
    Cyclo[(2S)-2-phenylglycyl-D-tryptophyl-L-lysyl-O-(phenylmethyl)-L-tyrosyl-L-phenylalanyl-(4R)-4-[[[(2-aminoethyl)amino]carbonyl]oxy]-L-prolyl]

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Lewis I, et al. J Med Chem. 2003 Jun 5;46(12):2334-44. 2. Bruns C, et al. Eur J Endocrinol. 2002 May;146(5):707-16. 3. Hofland LJ, et al. Eur J Endocrinol. 2005 Apr;152(4):645-54.
molnova catalog
related products
  • Octreotide acetate

    An octapeptide that mimics natural somatostatin pharmacologically, that is 200 times more potent than somatostatin.

  • Paltusotine

    Paltusotine is a nonpeptide, small molecule somatostatin type 2 (SST2) receptor agonist with high oral bioavailability. Paltusotine maintains GH and IGF-1 levels in acromegaly patients

  • Octreotide

    Octreotide is a synthetic long-acting cyclic octapeptide with pharmacologic properties mimicking those of the natural hormone somatostatin.